Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Quick Stats
Jan 30, 202665.8
AI Score
BUY1.12
Volume Ratio
Feb 03, 2026
Next Earnings
16
+ve Days (30d)
14
-ve Days (30d)
AMGN Stock Summary
Last updated Jan 30, 2026
AMGN is currently trading at $341.88, positioned above its 200-day moving average of $301.02, indicating a long-term uptrend. The stock has a 52-week range of $261.43 to $353.25.
Technical Analysis: The 50-day moving average stands at $333.3, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 55.73, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.262, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates AMGN at 65.8/100 with a BUY recommendation.
AMGN (Amgen Inc) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 55.73 |
| CMF (20) | 0.262 |
| ROC (10) | 3.417 |
| ADX (14) | 16.168 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 4.711 |
| AROONOSC (14) | 64.286 |
| WILLAMS %R (14) | -35.687 |
| MFI (14) | 57.894 |
AMGN Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
AMGN Price vs Max Options Open Interest
AMGN Max Change In Options Open Interest
AMGN Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
AMGN Daily Out of Money Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
AMGN Daily In the Money Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
AMGN Most Active Options by Volume(near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Amgen Inc is above both 50 Day and 200 Day SMA which is considered Bullish.
AMGN Moving Averages Analysis
Amgen Inc has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Jan 30, 2026
Amgen Inc has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jan 30, 2026
AMGN (Amgen Inc) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 342.54 |
| 20 | 335.53 |
| 30 | 333.47 |
| 50 | 333.3 |
| 100 | 314.72 |
| 200 | 301.02 |
AMGN Fundamental Analysis
| P/E (Forward) | 15.873 |
| P/E (Trailing) | 26.4467 |
| Market Cap ($) | 184.3 billion |
| Earnings/Share ($) | 12.94 |
| Net Proft Margin (%) | 0.1947 |
| Dividend/Share ($) | 9.39 |
| EPS Estimate Current Year ($) | 21.2796 |
| EPS Estimate Next Year ($) | 22.1136 |
| WallStreet Target Price ($) | 331.963 |
| Most Recent Quarter |
Amgen's Q4 earnings beat expectations with EPS of $4.09 vs $4.04 expected and Sales of $6.84B vs $6.76B expected. Amgen has launched two biosimilars to Humira, AMJEVITA and Imlygic, with a dual discount strategy. The stock is currently showing bearish technical signs.
Updated 2023-01-31 18:10:02